PSTX - Poseida Therapeutics, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
San Diego,
United States
Type: Equity
PSTX price evolution
PSTX
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $44.47 | $25.5 | $49.91 | $40.14 |
| Short term investments | $167.73 | $213.33 | $164.69 | $207.06 |
| Net receivables | $9.01 | $8.67 | $11.91 | $8.44 |
| Inventory | ||||
| Total current assets | $226.47 | $252.66 | $230.19 | $260.7 |
| Long term investments | ||||
| Property, plant & equipment | $40.78 | $42.95 | $44.41 | $46.32 |
| Goodwill & intangible assets | $5.55 | $5.55 | $5.55 | $5.55 |
| Total noncurrent assets | $47.41 | $49.59 | $51.02 | $52.92 |
| Total investments | $167.73 | $213.33 | $164.69 | $207.06 |
| Total assets | $273.88 | $302.25 | $281.21 | $313.62 |
| Current liabilities | ||||
| Accounts payable | $3.27 | $2.54 | $2.1 | $3.2 |
| Deferred revenue | $47.79 | $63.6 | $28.69 | $39.15 |
| Short long term debt | $5.95 | $5.91 | $5.86 | $5.82 |
| Total current liabilities | $71.32 | $76.97 | $49.89 | $48.69 |
| Long term debt | $79.47 | $80.35 | $81.22 | $82.07 |
| Total noncurrent liabilities | $98.87 | $101.62 | $96.03 | $107.37 |
| Total debt | $85.42 | $86.26 | $87.08 | $87.89 |
| Total liabilities | $170.18 | $178.59 | $145.91 | $156.06 |
| Shareholders' equity | ||||
| Retained earnings | -$594.29 | -$568.94 | -$537.16 | -$509.71 |
| Other shareholder equity | $0.13 | -$0.2 | -$0.28 | $0 |
| Total shareholder equity | $103.7 | $123.66 | $135.3 | $157.56 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $44.47 | $81.38 | $206.32 | $83.97 |
| Short term investments | $167.73 | $201.12 | $225.19 | |
| Net receivables | $9.01 | $9.09 | ||
| Inventory | ||||
| Total current assets | $226.47 | $298.56 | $213.87 | $314 |
| Long term investments | ||||
| Property, plant & equipment | $40.78 | $46.67 | $48.23 | $48.32 |
| Goodwill & intangible assets | $5.55 | $5.55 | $5.55 | $5.55 |
| Total noncurrent assets | $47.41 | $53.27 | $55.44 | $57.49 |
| Total investments | $167.73 | $201.12 | $225.19 | |
| Total assets | $273.88 | $351.84 | $269.31 | $371.48 |
| Current liabilities | ||||
| Accounts payable | $3.27 | $2.23 | $8.96 | $0.76 |
| Deferred revenue | $47.79 | $41.06 | $13.76 | |
| Short long term debt | $5.95 | $5.87 | $6.34 | $4.81 |
| Total current liabilities | $71.32 | $53.88 | $43.34 | $30.02 |
| Long term debt | $79.47 | $58.25 | $54.86 | $54.51 |
| Total noncurrent liabilities | $98.87 | $110.36 | $69.76 | $79.49 |
| Total debt | $85.42 | $88.75 | $61.2 | $59.31 |
| Total liabilities | $170.18 | $164.24 | $113.1 | $109.52 |
| Shareholders' equity | ||||
| Retained earnings | -$594.29 | -$470.86 | -$406.86 | -$281.88 |
| Other shareholder equity | $0.13 | -$0.15 | $0.01 | |
| Total shareholder equity | $103.7 | $187.59 | $156.21 | $261.97 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $25 | $9.35 | $20.01 | $10.34 |
| Cost of revenue | ||||
| Gross Profit | $25 | $9.35 | $20.01 | $10.34 |
| Operating activities | ||||
| Research & development | $42.05 | $37.48 | $39.19 | $38.05 |
| Selling, general & administrative | $8.86 | $8.09 | $8.68 | $11.81 |
| Total operating expenses | $50.9 | $45.57 | $47.87 | $49.86 |
| Operating income | -$25.91 | -$36.22 | -$27.86 | -$39.52 |
| Income from continuing operations | ||||
| EBIT | -$23.08 | -$29.43 | -$25.32 | -$36.82 |
| Income tax expense | $0.11 | |||
| Interest expense | $2.27 | $2.24 | $2.14 | $2.03 |
| Net income | ||||
| Net income | -$25.35 | -$31.78 | -$27.46 | -$38.85 |
| Income (for common shares) | -$25.35 | -$31.78 | -$27.46 | -$38.85 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $64.7 | $130.49 | $31.24 | |
| Cost of revenue | ||||
| Gross Profit | $64.7 | $130.49 | $31.24 | |
| Operating activities | ||||
| Research & development | $156.77 | $152.9 | $136.73 | $103.52 |
| Selling, general & administrative | $37.44 | $37.54 | $35.91 | $23.03 |
| Total operating expenses | $194.21 | $190.44 | $172.65 | $126.55 |
| Operating income | -$129.5 | -$59.95 | -$141.41 | -$126.55 |
| Income from continuing operations | ||||
| EBIT | -$114.65 | -$57.09 | -$121.62 | -$126.27 |
| Income tax expense | $0.11 | $0.54 | ||
| Interest expense | $8.67 | $6.37 | $3.36 | $3.51 |
| Net income | ||||
| Net income | -$123.43 | -$64 | -$124.97 | -$129.78 |
| Income (for common shares) | -$123.43 | -$64 | -$124.97 | -$129.78 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | -$25.35 | -$31.78 | -$27.46 | -$38.85 |
| Operating activities | ||||
| Depreciation | $1.44 | $1.44 | $1.41 | $1.32 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $5.06 | $5.12 | $5.47 | $7.48 |
| Total cash flows from operations | -$28.74 | $7.89 | -$33.31 | -$38.01 |
| Investing activities | ||||
| Capital expenditures | -$0.31 | -$0.79 | -$1.18 | -$0.78 |
| Investments | $48.02 | -$46.45 | $44.26 | -$3.63 |
| Total cash flows from investing | $47.71 | -$47.24 | $43.07 | -$4.42 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $14.42 | $0.93 | ||
| Net borrowings | ||||
| Total cash flows from financing | $14.94 | $1.19 | ||
| Effect of exchange rate | ||||
| Change in cash and equivalents | $18.97 | -$24.41 | $9.77 | -$41.23 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$123.43 | -$64 | -$124.97 | -$129.78 |
| Operating activities | ||||
| Depreciation | $5.61 | $5.17 | $4.55 | $2.59 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $23.13 | $18.93 | $16.7 | $7.22 |
| Total cash flows from operations | -$92.17 | -$26.77 | -$102.54 | -$113.33 |
| Investing activities | ||||
| Capital expenditures | -$3.07 | -$3.91 | -$2.62 | -$16.91 |
| Investments | $42.2 | -$199.42 | $225 | -$187.52 |
| Total cash flows from investing | $39.13 | -$203.33 | $222.38 | -$204.43 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $15.35 | $75.3 | $2.52 | $310.11 |
| Net borrowings | $28.55 | -$0.33 | ||
| Total cash flows from financing | $16.13 | $105.16 | $2.52 | $313.94 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$36.91 | -$124.95 | $122.36 | -$3.82 |
News
Fundamentals
| Market cap | $191.27M |
|---|---|
| Enterprise value | $232.22M |
| Shares outstanding | 95.64M |
| Revenue | $64.70M |
|---|---|
| EBITDA | -$109.04M |
| EBIT | -$114.65M |
| Net Income | -$123.43M |
| Revenue Q/Q | 148.68% |
| Revenue Y/Y | -50.42% |
| P/E ratio | -1.55 |
|---|---|
| EV/Sales | 3.59 |
| EV/EBITDA | -2.13 |
| EV/EBIT | -2.03 |
| P/S ratio | 2.96 |
| P/B ratio | 1.85 |
| Book/Share | 1.08 |
| Cash/Share | 0.47 |
| EPS | -$1.29 |
|---|---|
| ROA | -42.16% |
| ROE | -94.90% |
| Debt/Equity | 1.64 |
|---|---|
| Net debt/EBITDA | -1.15 |
| Current ratio | 3.18 |
| Quick ratio | 3.18 |